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Multiple sclerosis (MS) is an autoimmune disease of the central nervous system
(CNS) that is associated with demyelination and neuronal loss. Over recent years, the
immunological and neuronal effects of tryptophan (Trp) metabolites have been largely
investigated, leading to the hypothesis that these compounds and the related enzymes
are possibly involved in the pathophysiology of MS. Specifically, the kynurenine pathway
of Trp metabolism is responsible for the synthesis of intermediate products with potential
immunological and neuronal effects. More recently, Trp metabolites, originating also from
the host microbiome, have been identified in MS, and it has been shown that they are
differently regulated in MS patients. Here, we sought to discuss whether, in MS patients, a
specific urinary signature of host/microbiome Trp metabolism can be potentially identified
so as to select novel biomarkers and guide toward the identification of specific metabolic
pathways as drug targets in MS.
Keywords: tryptophan, urine, signature, metabolite, multiple sclerosis, kynurenine, indole-3-propionic acid,
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INTRODUCTION
The levels of the essential amino acid Tryptophan (Trp) and the function of Trp derivatives
have long been a subject of research interest in autoimmunity. Mammals utilize Trp for different
reasons, such as protein synthesis, the release of immunomodulant catabolites, and the synthesis
of the aminergic neurotransmitter serotonin, the neurohormone melatonin, several neuroactive
kynuramine metabolites of melatonin, and trace amine tryptamine. Indeed, Trp is metabolized by
the mammalian host cells via four different pathways, of which the most relevant is the kynurenine
pathway. The other two pathways provide the transamination and decarboxylation of Trp. The
hydroxylation in serotonin occurs for only 1% of dietary Trp. Interestingly, the metabolic products
of the kynurenine pathway are known to have several effects on vascular system, immune system,
immunotolerance, and infections.
From the time when Trp and Trp derivatives were administered in multiple sclerosis (MS) to
treat autoimmunity empirically (1), many advances have been made on the knowledge of Trp
metabolic functions (2). It is almost universally agreed that the catabolism of Trp has different
physiological implications, such as having antimicrobial and immunomodulant properties. For all
of these reasons, Trp metabolites have been largely investigated in MS (3).
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From a pathophysiological point of view, MS is characterized,
from its earliest stages, by the coexistence of acute focal
inflammation, glial cell hyperactivation, and progressive neuro-
axonal loss (4). In the relapsing-remitting phenotype of
the disease, inflammatory mechanisms are prominent and
are largely responsible for the clinical manifestations of the
disease, which are usually transient and recurrent (4). On
the contrary, the progressive phenotype of the disease, which
often follows the relapsing-remitting phase, is thought to be
largely sustained by neurodegenerative mechanisms, probably
as the ultimate consequence of previous recurrent episodes
of brain and spinal cord inflammation (5). Additionally, the
development of meningeal lymphocytic infiltrates and B-cell
follicle-like structures in progressive MS patients may enhance
neurodegenerative phenomena (6). MS can be extremely variable
between individuals, with huge differences in the frequency of
episodes of focal inflammation, in the possibility of the transition
from the relapsing-remitting to the progressive phenotype, in
the rate of progression, and in disability outcomes (7). Among
the numerous factors potentially underlying this variability, a
link between environment, microbial commensals, and host
immunity has been suggested (8).
The earlier findings that Trp metabolized by indoleamine-
2,3-dioxygenase (IDO) along the kynurenine pathway, plays
a role in the pathophysiology of neuroinflammatory and
neurodegenerative disorders, led several groups of researchers
to study the changes in the levels of kynurenines in plasma,
urine and cerebrospinal fluid in MS patients or in mice with
experimental autoimmune encephalitis (EAE), the animal model
of MS (9–13).
Systemic activation of Trp metabolism may have critical
effects in MS. For instance, it has been demonstrated that
Trp degradation is increased in the brain during the acute
phase of EAE (14). Experimental results obtained by the use
of the pharmacological inhibitor of IDO (1-methyl-Trp) also
support a role for this pathway in MS. Indeed, the treatment
of mice with 1-methyl-Trp resulted in EAE exacerbation (14).
This latter evidence might suggest a protective role of IDO
metabolites in EAE, although some downstream products of
the kynurenine pathway, such as quinolinic acid, may also
promote neurotoxicity.
Recently, metabolomics provided new insights into the
research field of MS immunopathology, showing significant
promise for unraveling the sources of disease heterogeneity,
for understanding the interaction between the environment
and immunity, and for monitoring disease progression and
response to treatment in MS patients. For instance, untargeted
metabolomics has been used recently in plasma samples of EAE
mice to find a signature of 44 metabolites corresponding to six
major pathways that were considerably altered, including bile
acid biosynthesis, taurine metabolism, tryptophan and histidine
metabolism, and linoleic acid andD-argininemetabolic pathways
(9). Interestingly, the signature also included various metabolites
categorized under the xenobiotics class, which are normally
not synthesized in the body but can be metabolized by the
microbiome as equolsulphate, homostachydrine, hippurate, and
a Trp-derivative, indoleacrylate, which is also excreted in urine.
Besides, another Trp-derivative metabolite produced by the
microbiota, indole-3-propionic acid, was found to be elevated in
the plasma of EAE mice (9).
From a clinical perspective, one of the most important
outcomes in MS is the risk of developing a progressive disease
course (15). Indeed, while the relapsing-remitting phase can
be effectively managed with immunomodulatory drugs, few
treatments are available for progressive MS, and the progression
of neurological disability is difficult to manage (16). In this
context, Lim et al. recently wrote a paper targeted at deciphering
a metabolic signature in serum to predict the transition
from relapsing-remitting to progressive MS and to find a
metabolic biomarker. Accordingly, they examined the role of
the kynurenine pathway in MS progression and found that this
pathway has a strong association with MS subtypes, correlating
with disease severity scores (17).
Metabolomics has also been done on urine samples, which
are readily available for analysis, and this has been used
as a potential source of biomarkers in MS (18). Nuclear
magnetic resonance (NMR) spectroscopy of urine allowed for
the identification of metabolites that differentiated EAE-mice
from healthy andMS drug-treated EAEmice (19). More recently,
the metabolic profile in urine of mice bearing chronic EAE was
performed with an untargeted combinedmetabolomics approach
using gas chromatography- and liquid chromatography-mass
spectrometry (GC-MS and LC-MS) (20). The authors identified
eight metabolites characterizing EAE mice that are commonly
found in plasma and urine and are potential biomarkers (20).
Interestingly, the amino acid metabolism was primarily affected
during EAE, as supported by urine analysis (20).
It is worth noting that in the diagnostic and/or therapeutic
work-up of MS patients, standard urine analysis is usually
performed, which makes urine sampling feasible for other
investigations also. Additionally, urine is a metabolite-rich
fluid that reflects the body’s homeostasis and gut microbiome
changes. Thus, a combined metabolomics analysis in urine,
where both changes in host inflammatory/metabolic responses
and in gut microbiome during MS may be highlighted, might
help identifying novel biomarkers. This may provide a model
to characterize pathogenic aspects of MS and to develop
therapeutic approaches. We have therefore decided to perform
an observational study aimed at investigating a broad panel
of Trp metabolites, of both human and microbial origin, in
urine samples from relapsing-remitting MS (RRMS) patients, in
order to specifically investigate the possible relationship of Trp
metabolites with the earliest inflammatory phase of the disease.
We have compared the findings in RRMS patients to a control
group of healthy individuals, and we have specifically looked for
differences between MS patients and controls and for possible
associations with disease characteristics.
MATERIALS AND METHODS
Patients
Urine samples were obtained from 47 consecutive patients
with RRMS and 43 healthy controls, i.e., individuals without
MS or autoimmune or inflammatory diseases. Patients and
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healthy controls were prospectively and consecutively recruited
over a 1-year period at the Section of Neurology, Department
of Medicine, University of Perugia (Italy). For MS patients,
inclusion criteria were: (i) a diagnosis of RRMS according to
the 2010 revision of the McDonald criteria (21); (ii) no recent
history of infectious disorders (i.e.,<30 days before the inclusion
in the study); (iii) age >18 years. The study was approved
by the local Ethics Committee (# 2925/16), and patients gave
informed consent for the collection of samples and subsequent
analysis. The main demographic and clinical characteristics of
patients were collected by experienced neurologists. For each
patient, the disability level at the time of urine sampling was
quantified by scoring on the Expanded Disability Status Scale
(EDSS) (22). Urine samples were collected at the same time
of the day (between 09:00 and 12:00) in order to avoid any
potential confounding effect of diurnal rhythm. Urine samples
were subsequently analyzed by laboratory technicians who were
blinded to clinical data.
Urine Analysis
Urine Trp metabolites were assessed by means of high-
performance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS). We used a targeted approach where a set
of host or microbial metabolites derived from Trp were
measured in urine. Details of HPLC-MS/MS analysis are
reported in the Supplementary Methods. The following Trp
metabolites and ratios were determined: (i) Trp; (ii) kynurenine;
(iii) anthranilate; (iv) kynurenine/Trp (K/T) ratio; (v)
kynurenine/anthranilate (K/A) ratio; (vi) 3-hydroxykynurenine;
(vii) 3-hydroxyanthranilate; (viii) serotonin; (ix) tryptamine; (x)
indole-3-acetic acid; (xi) indole-3-acetamide; (xii) indole-3-lactic
acid; (xiii) indole-3-propionic acid.
Statistical Analysis
Continuous variables are reported as mean± standard deviation
(SD) if normally distributed or as median, interquartile range
(IQR), if non-normally distributed. Logarithmic transformation
was applied to Trp metabolite values in order to reach normality,
as verified with the Shapiro-Wilk test. Differences of (log)
Trp metabolite values between groups were tested with the
Student’s t-test, while their association with continuous variables
was tested with Pearson’s correlation coefficient test. General
linear models were performed for multivariable analysis. All
tests were two-sided, and the significance threshold was set to
p < 0.05. IBM SPSS Statistics software version 22 was used for
statistical analysis.
RESULTS
The Trp Metabolic Urinary Signature of
RRMS Patients
The main demographic and clinical characteristics of RRMS
patients and controls are reported in Table 1. A total of 35
patients (74.5%) were under disease modifying drugs at the time
of urine sampling. In the entire cohort of MS patients and
controls, females had significantly lower urinary tryptophan (p
= 0.001), kynurenine (p = 0.01), anthranilate (p = 0.01), and
serotonin (p = 0.01) concentrations (p = 0.04) than males (data
TABLE 1 | Main patient and control characteristics.
RRMS HC p-value
Na 47 43 ND
Age (years)b 31.8 ± 9.7 32.7 ± 10.6 NS
F/M 40/7 27/16 p = 0.02


















EDSSb 1.6 ± 0.5 ND ND
Recent relapse (<30 days)a 9 (19.1%) ND ND
aData are shown as number (percentage).
bData are shown as mean ± standard deviation.
EDSS, Expanded Disability Status Scale; HC, healthy controls; ND, not determinable; NS,
not significant; RRMS, relapsing-remitting multiple sclerosis.
not shown). After adjusting for gender, RRMS patients had a
significantly lower urine concentration of kynurenine (1.4µM,
IQR: 0.5–3µM vs. 4µM, IQR: 1.9–6.8µ, p = 0.01) and a
lower K/T ratio (19, IQR: 15.5–27.5 vs. 29.8, IQR: 13.5–43, p =
0.04) than healthy controls (Figure 1). In contrast, no significant
difference between patients and control subjects was found in
the other Trp analyzed metabolites (see Materials and Methods).
Within the RRMS cohort, Trp metabolites were not correlated
with age and disease duration. In contrast, we found significant
correlations between EDSS scores and urine concentrations of
the following metabolites: (i) tryptophan (r = 0.5, p = 0.001),
(ii) K/T (r = −0.3, p = 0.03), and (iii) indole-3-propionic acid
(r = 0.5, p < 0.001; Figure 1). In a multivariate model taking
into account age and gender, the correlations were confirmed for
tryptophan (β = 0.1, p < 0.04), K/T (β = −0.02, p = 0.003), and
indole-3-propionic acid (β = 4.4, p = 0.001). Finally, in RRMS
patients, we found no difference in treated compared to untreated
individuals, nor were there significant variations depending on
the type of ongoing treatment.
In our cohort of RRMS patients, we found that urinary Trp
metabolites were differently expressed in patients who had had
a recent relapse (i.e., within 30 days before urine sampling).
Specifically, the urine K/A ratio was significantly lower in patients
with a recent relapse than in clinically stable patients (2.3µM,
IQR: 1.2–4.3µM vs. 6.6µM, IQR: 2.5–13.7µM, p = 0.03),
with a significantly higher urinary anthranilate concentration in
relapsing vs. stable patients (1.1µM, IQR: 0.5–1.8µMvs. 0.2µM,
IQR: 0.1–0.3µM, p = 0.02) (data not shown). Finally, relapsing
patients had significantly higher urine indole-3-propionic acid
concentrations than stable patients (0.05µM, IQR: 0–0.1µM vs.
0.01µM, IQR: 0–0.04µM, p= 0.04; Figure 1).
DISCUSSION
The pathophysiology of MS is extremely complex since it
relies on the interplay between several players, such as the
peripheral immune system, central nervous system resident
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FIGURE 1 | In patients with relapsing-remitting multiple sclerosis (RRMS), we found a significantly lower urinary concentration of kynurenine (A) (median and
interquartile range are reported) and kynurenine/tryptophan (K/T) ratio (B) (median and interquartile range are reported) than in healthy controls (HC). Additionally, a
significant negative correlation between urinary K/T and the Expanded Disability Status Scale (EDSS) score at urine sampling was found (C). In RRMS patients in
proximity (i.e., <30 days) to a clinical relapse, significantly higher urinary indole-3-propionic acid concentrations were found than in clinically stable RRMS patients
(D) (median and interquartile range are reported). Moreover, urinary indole-3-propionic acid concentrations were positively correlated with the EDSS score at urine
sampling (E). *p < 0.05.
immune cells and glial cells, and neurons (23). MS is supposed
to have a multifactorial etiology, and different environmental
and genetic risk factors may play a role in determining the risk
of developing the disease and in driving different phenotypic
disease characteristics (24). Interestingly, Trp metabolism can
be influenced both by the individual genetic background and
interaction with environmental factors, such as diet. A great deal
of interest is now being taken in determining how microbial
commensals can modulate the host immune system, since this
could lead to the potential discovery of new therapeutic targets.
In this study, we found some intriguing preliminary clues that
a dysbalanced human Trp metabolism may have an association
with MS, a finding that is supported by the evidence that this
specific metabolism plays a central role in the control of immune
activation (25). Specifically, we found that in the earliest and
most inflammatory phenotype of MS, i.e., RRMS, there is a
specific urinary Trp metabolite signature, which is characterized
by a lower concentration of kynurenine and a lower K/T ratio
than in healthy controls. Additionally, K/T was negatively and
independently correlated with the degree of disability at the
time of urine sampling. Taken together, these findings seem
to suggest that in the earliest stages of MS, a reduced Trp
metabolism toward kynurenine can be found, and the lower
the synthesis of kynurenine, the worse the degree of clinical
impairment due to MS. Of interest, the synthesis of kynurenine
via the IDO1 enzyme has been hypothesized to enhance the
conversion of naïve T CD4+ cells into regulatory T cells (26),
and kynurenine has shown immunoregulatory properties via
the activation of the Aryl hydrocarbon Receptor (AhR) (27).
Thereafter, reduced synthesis of kynurenine and a subsequent
lower urinary kynurenine and K/T ratio may play a role in the
pathophysiology of MS, where dysfunctional regulatory T cells
favor autoimmune processes in the central nervous system (28).
From a biological point of view, once Trp is converted
into kynurenine, the kynurenine pathway of Trp degradation
is activated, which leads to the synthesis of a variety of
compounds with both neurotoxic and neuroprotective properties
that can influence MS pathology and, consequently, the
degree of neurological impairment (29). Among the human
urinary kynurenine downstream metabolites that we have
measured in our study (i.e., 3-hydroxykynurenine and 3-
hydroxyanthranilate), we did not find any significant association
with the degree of disability apart from the above-mentioned
negative correlation between K/T and EDSS. However, when
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interpreting this latter result, it should be noted that most of
our patients had a low disability score. Therefore, the correlation
between urinary Trp metabolites and the degree of neurological
impairment deserves further confirmation on larger and more
heterogeneous cohorts of MS patients, also including patients
with progressive MS and with a longer disease duration.
Our findings are different from those reported for serum by
Lim et al., who described higher serum K/T in MS patients than
in controls (17). It is possible that this opposite result relies on
the use of different biological samples (i.e., urine vs. serum),
potentially reflecting different phases of Trp metabolism and/or
different activities of the involved enzymes at different body
sites. In this context, in order to understand the relationship
between Trp metabolite concentrations in different biofluids,
studies examining urine, blood, and cerebrospinal fluid in the
same subjects at the same time are highly desirable.
Another possible explanation for the discrepancy between
our findings and those coming from the literature might be the
different characteristics of the enrolled patients. For instance, in
the cohorts investigated by Lim et al., progressive MS patients
were also included, and none of the patients was under disease-
modifying drugs. Moreover, in the same paper, no information
was provided on recent disease activity, although it can be
assumed that enrolled patients had no history of recent relapses
since, in the previous 3 months, they had not undergone steroid
therapy (17).
The latter point could be extremely important in influencing
Trpmetabolite concentrations in body fluids, since we found that
their urinary concentrations change in proximity to a clinical
relapse, with a decrease in K/A and an increase in indole-3-
propionic acid.
The decrease in K/Amight either reflect a reduction in urinary
kynurenine, a compound with immunoregulatory properties
as discussed above, or an increase in anthranilate, or both.
Of interest, anthranilate has been shown to increase in the
blood in a wide range of human diseases, probably with a
sort of “cleaning up” effect after an acute injury (30). Indeed,
anthranilate has been associated with an antagonism to other
neurotoxic kynurenines, such as quinolinic acid, as well as with
a reduction in oxidative stress and in inflammatory responses
(30–32). Thereafter, the decrease in urinary K/A in proximity
of MS clinical relapses could reflect both a decrease in urinary
kynurenine, which could enhance inflammatory responses, and
an increase in urinary anthranilate, probably as a consequence of
compensatory mechanisms following acute inflammation.
Also, the association between indole-3-propionic acid andMS
disease activity is particularly interesting, since this molecule is
one of the Trp-derived metabolites produced by the microbiota,
called post-biotics (33, 34), that have been deeply investigated in
recent years because of their presence in peripheral tissues and
their ability to bind xenobiotic receptors. Indole-3-propionic acid
is now known to contribute to changes in body weight gain on a
tryptophan-rich diet (35). It may destroy indoxyl sulfate-induced
expression of fibrosis and inflammation in kidney proximal
tubular cells (36). More interestingly, it is also considered an
antioxidant and has been reported to be neuroprotective (37).
More recently, the mechanism by which the indole-3-propionic
acid interacts with the mammalian host epithelial barrier has
been described: the xenobiotic receptor pregnane X receptor
(PXR) is, in fact, able to recognize this metabolite and reduce gut
inflammation (38, 39). Interestingly, high blood levels of indole-
3-propionic acid have also been found by other research groups
in mice with EAE (9).
Since indole-3-propionic acid has been shown to have
an antioxidant effect (40), its urinary increase may reflect
an additional compensatory mechanism, driven by microbial
commensals, trying to counteract the negative effects of acute
inflammation. On the other hand, it is not possible to rule out
a deleterious effect of indole-3-propionic acid, given the positive
correlation that we have found between this Trp derivative and
the degree of disability. Further studies investigating the possible
immune and neuronal effects of indole-3-propionic acid are
therefore needed to understand its pathophysiological role inMS.
In conclusion, although our findings are preliminary and
deserve further confirmation on larger and unselected cohorts,
they seem to suggest that a misbalanced human Trp metabolism
is associated with MS, probably reflecting disease activity
and severity. More interestingly, we found some clues that
commensal microbials may interact with the host, especially in
proximity to MS relapses, by synthesizing compounds such as
indole-3-propionic acid.
FUTURE PERSPECTIVES
The study of Trp metabolites in MS is providing the scientific
community with fascinating clues on the interaction between
the microbiota and the human immune system in the context
of autoimmune diseases. Our study, performed on urinary
Trp metabolites, showed some preliminary and very interesting
results, such as reduced urinary K/T in RRMS and its negative
correlation with disability measures. In this sense, an altered
Trp metabolism could either precede or follow autoimmune
pathophysiological processes taking place in MS and could have
an association with acute episodes of inflammatory activity
during a chronic disease such as MS. More generally, it will
be fundamental to understand if Trp metabolites are associated
with a pathogenic effect and/or if they reflect the bystander
activation of compensatory mechanisms to the ongoing MS-
related autoimmunity. This step is required in order to proceed
further in the Trp metabolism research field in search of
novel potential therapeutic targets. In the near future, the
study of Trp metabolism with the help of artificial intelligence
and machine learning may become extremely effective in
assisting medical doctors and biologists to address and solve
complex diagnostic, prognostic, and therapeutic tasks. Indeed,
probabilistic graphical models may be used to decipher or predict
how the host and the microbiota share a common metabolic
nutrient such as Trp and how this shared catabolism may be
affected during immunopathology. Additionally, further studies
on larger cohorts of MS patients are required in order to
better investigate the correlations between Trp metabolites in
different biofluids and more specific disease characteristics, such
as neuroradiological and cerebrospinal fluid findings.
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